New drug shows promise for dialysis Patients' hormone imbalance

NCT ID NCT06434961

Summary

This study tested whether a new drug called SHR6508 could safely and effectively treat a serious hormone imbalance (secondary hyperparathyroidism) in people with kidney failure who are on regular dialysis. It involved 498 participants in China and compared the drug's effects to a placebo. The main goal was to see if the drug could significantly lower the levels of a specific hormone (iPTH) in the blood.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510000, China

Conditions

Explore the condition pages connected to this study.